Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ: QNTM) has successfully closed the final tranche of its previously announced financing, raising $2.42 million in Debenture Units. This completion brings the total financing to $5 million, following amendments made on January 20, 2025, and improved terms announced on March 7, 2025.
The funds will be allocated to advance research and development of drug candidates, commercialization efforts, and general working capital. The company projects these funds will sustain operations until at least Q1 2027. Additionally, Quantum has initiated the development of rekvry™, a new alcohol misuse treatment designed for emergency and hospital settings, aimed at reducing healthcare costs and resource burden.
Quantum BioPharma (NASDAQ: QNTM) has announced the renewal of two service contracts. The company has extended its agreement with King Tide Media for a one-month term starting April 1, 2025, at a cost of US$15,000. Additionally, they have renewed services with IR Agency for a 60-day period beginning April 1, 2025, for US$50,000.
Quantum BioPharma (NASDAQ:QNTM) has reported strong financial improvements for Q4 and full year 2024. The company's cash position strengthened to $12.1M USD, up from $11.1M in 2023. Operating expenses decreased by 32% to $16.1M, while net loss improved by 18% to $14.9M compared to 2023.
Key developments include:
- Completion of unbuzzd™ clinical trial showing 40% faster reduction in Blood Alcohol Concentration
- Successful Phase 1 trial of Multiple Sclerosis drug Lucid-21-302
- Material Uncertainty Related to Going Concern removed with sufficient working capital through January 2027
- Strategic purchase of $3.5M in Bitcoin and cryptocurrencies
- Dual listing on Upstream exchange
The company's licensee, Celly Nutrition, is exploring an IPO and has secured distribution agreements in Puerto Rico, Caribbean, and parts of Central and South America for unbuzzd.
Quantum BioPharma (NASDAQ: QNTM) reported strong financial improvements for FY2024, removing Material Uncertainty Related to Going Concern. Cash position strengthened to $12.1M USD (up from $11.1M in 2023), with operating expenses reduced by 32% to $16.1M USD.
Key highlights include:
- Net loss improved 18% to $14.9M USD
- Net cash used in operations decreased 36% to $6.9M USD
- Successfully completed clinical trials for unbuzzd™ alcohol detoxification beverage, showing 40% faster BAC reduction
- Completed Phase 1 trial for Multiple Sclerosis drug Lucid-21-302, demonstrating safety and tolerability
- Expanded distribution network through FUSION Distribution Group for Caribbean markets
- Invested $3.5M in cryptocurrencies and dual-listed on Upstream exchange
Quantum BioPharma (NASDAQ: QNTM) has announced the appointment of Terry Lynch to its Board of Directors, replacing Dr. Sanjiv Chopra who will continue as an advisor. Lynch, known for founding Save Canadian Mining, brings extensive experience in fighting stock market manipulation and naked short selling.
Lynch currently serves as CEO of Power Metallic Mines, which recently secured a $50 million financing. He is also a co-founder of Cardiol Therapeutics and consultant to bionxt solutions. The company has granted Lynch 50,000 stock options at C$9.90 per Class B Share, expiring March 26, 2027.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition has launched new unbuzzd™ On-the-Go Powder Stick Packs in 8-pack display boxes for U.S. retail distribution. unbuzzd™ is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
The new format features TSA-compliant, pocket-sized powder sticks available in 3-pack, 8-pack, and 18-pack options, targeting convenience, liquor, and drug stores. The product is available on amazon.com and unbuzzd.com. Quantum BioPharma owns 25.71% of Celly Nutrition and receives a 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% perpetually.
The company retains full rights to develop similar products for pharmaceutical and medical uses. The launch targets the estimated $2.1 billion global hangover cure products market, supported by recent clinical trials proving the product's effectiveness in reducing blood alcohol concentration.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency portfolio with an additional USD $1,500,000 investment in Bitcoin (BTC) and other cryptocurrencies, following Board approval. This strategic move brings the company's total crypto investment to USD $3,500,000.
The company will continue accepting future financings and transactions in cryptocurrency, viewing it as a potential hedge against the dollar and an opportunity for shareholder returns. All crypto assets are held with a compliant custodian, and transactions adhere to financial and audit regulations. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302 (Lucid-MS), a novel multiple sclerosis drug. The Safety Review Committee confirmed the drug was well-tolerated with no safety concerns or serious adverse events reported.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound featuring a unique mechanism of action. Preclinical models demonstrated its ability to stabilize the myelin sheath surrounding nerve fibers, potentially protecting against demyelination - a key characteristic of MS that leads to progressive disability.
Following this milestone, the company is preparing to advance to Phase 2 trials in MS patients, moving closer to their goals of drug approval and commercialization.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency holdings with an additional USD $1,000,000 investment in Bitcoin (BTC) and other cryptocurrencies, bringing its total crypto investment to USD $2,000,000. The investment, approved by the Board of Directors, is part of the company's strategic efforts to hedge against the Canadian dollar and potentially provide returns for shareholders.
The company has established infrastructure to accept cryptocurrency for financing and other transactions, with all digital assets being held by a fully compliant custodian. Quantum BioPharma emphasizes its commitment to maintaining compliance with financial and audit regulations while reserving the right to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has engaged MZ Group to lead its strategic investor relations and financial communications program. MZ will develop and implement a comprehensive capital markets strategy to increase the company's visibility in the investment community.
The company is developing products focused on brain disorders and alcohol health, including unbuzzd™ and rekvry™, which address excessive alcohol use - a problem costing the U.S. approximately $249 billion annually. Additionally, Quantum is working on a potential first-in-class treatment for demyelinating diseases, including Multiple Sclerosis, which affects nearly 1 million people in the U.S. and 2.8 million worldwide.
The MZ engagement involves a two-month initial period at $10,000 per month, with automatic monthly renewals thereafter. The agreement can be terminated by either party with fifteen days' notice.